Reference:WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth report -: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
||
| Line 9: | Line 9: | ||
}} | }} | ||
{{:Document:WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth report}} | {{:Document:WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth report}} | ||
{| class="gplx-infobox" | |||
{| class=" | |||
|- | |- | ||
! | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Scope | |||
| G | | G | ||
|- | |- | ||
! | ! Document part | ||
| - | | - | ||
|- | |- | ||
! | ! Language | ||
| EN | | EN | ||
|- | |- | ||
! | ! Original entry by | ||
| Florian Adragna | | Florian Adragna | ||
|- | |- | ||
! | ! Contributors | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (EN) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (original language) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (FR) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Comment | ||
| GMP documentation principles | | GMP documentation principles | ||
|} | |} | ||
== | == Content == | ||
Annex 3: WHO good manufacturing practices: main principles for pharmaceutical products | Annex 3: WHO good manufacturing practices: main principles for pharmaceutical products | ||
[...] | [...] | ||
Revision as of 14:27, 29 June 2026
| Document information | |
|---|---|
| Reference | WHO WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-fifth
report |
| Validity area | WHO |
| Scope(s) | G |
| Document name | WHO - EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS |
| Version / Revision | Forty-fifth
report |
| Status | N.A. |
| Document type | Other |
| Language(s) | EN |
| Description | WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS
Forty-fifth repor |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Scope | G |
| Document part | - |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags (EN) | |
| Tags (original language) | |
| Tags (FR) | |
| Comment | GMP documentation principles |
Content
Annex 3: WHO good manufacturing practices: main principles for pharmaceutical products [...] 15. Documentation [...] 15.6 Where documents require the entry of data, these entries should be clear, legible and indelible. Sufο¬cient space should be provided for such entries.
15.7 Any alteration made to a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded. [β¦] Annex 4: WHO guidelines on good manufacturing practices for blood establishments [β¦] 5.2 Document control [...] 5.2.1 Document management [β¦] When a document has been revised, the document management system should function in such a way as to prevent the inadvertent use of documents that have been superseded. [...]
